You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201521 - 201530 of 207726 results
  1. SBIR TOPIC 314: DEVELOPMENT OF A HUMAN TISSUE CULTURE SYSTEM THAT MIMICS THE TUMO

    SBC: Vivo Biosciences Inc            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. SBIR TOPIC 314: DEVELOPMENT OF A HUMAN TISSUE CULTURE SYSTEM THAT MIMICS THE TUMO

    SBC: Nortis, Inc.            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 313 PHASE I; RNAI CANCER THERAPEUTICS USING NANOTECHNOLOGY; HHSN2612013000

    SBC: GENESEGUES INC            Topic: NCI

    The design, fabrication, characterization, and preclinical evaluation of novel nanoparticle-based drug formulations capable of delivering candidate RNAi therapeutics for the treatment of cancer. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. SBIR TOPIC 313: RNAI CANCER THERAPEUTICS USING NANOTECHNOLOGY. PHASE I. HHSN26120

    SBC: Avidity Biosciences LLC            Topic: NCI

    The design, fabrication, characterization, and preclinical evaluation of novel nanoparticle-based drug formulations capable of delivering candidate RNAi therapeutics for the treatment of cancer. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC 316 PHASE I: GENETIC ANALYSIS OF CTCS AT THE SINGLE CELL LEVEL; HHSN261201

    SBC: Cellecta, Incorporated            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 316 PHASE I: OMICS CHIPS FOR CTC ISOLATION AND MOLECULARY ANALYSIS; HHSN261

    SBC: NEWOMICS INC.            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 316 PHASE I: DETECTION, ISOLATION, AND ANALYSIS OF SINGLE CTCS; HHSN2612013

    SBC: PGXL TECHNOLOGIES LLC            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. SBIR PHASE I TOPIC 318: CYP1B1*3 GENOTYPE AND IMPACT ON DOCETAXEL MOA; HHSN261201

    SBC: INTEGRATED LABORATORY SYSTEMS, LLC            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NCI

    Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and globally increases the adaptive immune response and resultsin an enhanced response to the cancer. In a subset of patients, this leads to longer Progression Free Survival (PFS), and in some cases remission ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. SBIR TOPIC321:CHEMICALLY DEFINED GLYCAN LIBRARIES FOR REFERENCE STANDARDS AND GLY

    SBC: OMICRON BIOCHEMICALS, INC.            Topic: NCI

    Cell-surface oligosaccharides appended to proteins and lipids are key binding epitopes in many critical biological processes, including bacterial infection, cell development and the immune response. Understanding these processes at the molecular level requires access to a wide range of oligosaccharides of known structure to support investigations of enzyme substrate binding and specificity, to ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government